Cutaneous Squamous Cell Carcinoma (cSCC) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035

Cutaneous Squamous Cell Carcinoma (cSCC) Market Outlook

Thelansis's "Cutaneous Squamous Cell Carcinoma (cSCC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cutaneous Squamous Cell Carcinoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Cutaneous Squamous Cell Carcinoma (cSCC) Overview

Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer, arising from malignant transformation of epidermal keratinocytes driven predominantly by cumulative ultraviolet radiation-induced DNA damage, with additional risk factors including immunosuppression, chronic wounds, human papillomavirus infection, arsenic exposure, and inherited conditions including xeroderma pigmentosum. Somatic mutations in TP53, CDKN2A, NOTCH1, and HRAS alongside high tumour mutational burden characterise the genomic landscape. The majority of cSCCs are localised and curable with surgical excision, however high-risk features including tumour diameter exceeding 2cm, poor differentiation, perineural invasion, deep tissue invasion, and immunosuppressed host status confer elevated recurrence and metastatic risk warranting multidisciplinary evaluation. Diagnosis is established by excisional or incisional biopsy with histopathological assessment; sentinel lymph node biopsy and cross-sectional imaging address regional and distant staging in high-risk disease. Surgical excision with appropriate margins remains the cornerstone of localised disease management, with Mohs micrographic surgery offering superior margin control for high-risk facial and anatomically sensitive lesions. Adjuvant radiotherapy addresses high-risk resected disease with adverse pathological features. Cemiplimab, an anti-PD-1 checkpoint inhibitor, is the established standard of care for locally advanced unresectable or metastatic cSCC, delivering durable responses and meaningful survival benefit. Pembrolizumab provides an approved alternative in eligible patients. Prognosis is excellent for localised disease; immunosuppressed patients warrant intensified surveillance given substantially elevated recurrence and progression risk, with multidisciplinary skin cancer team involvement integral to high-risk disease management.

Key Highlights

• In Germany, incident cSCC cases are projected to increase from 38,675 in 2025 to 44,883 by 2035, reflecting a growing disease burden driven by aging populations and cumulative UV exposure.
• cSCC is the second most common non-melanoma skin cancer, with a subset of patients progressing to locally advanced or metastatic disease.
• Rising incidence is associated with increased life expectancy, immunosuppression, and improved detection rates.
• Growing adoption of immunotherapy is improving outcomes in advanced cSCC patients.

Market Overview

• The Germany cSCC market is projected to grow from $189M in 2025 to $357M by 2035.
• Market growth is driven by:
• Increasing incidence and diagnosis rates
• Adoption of immune checkpoint inhibitors for advanced disease
• Future growth will depend on earlier diagnosis and expansion of immuno-oncology therapies.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Replimune, Inc.
• Incyte Corporation
• Regeneron Pharmaceuticals
• Merck Sharp & Dohme LLC
• Philogen S.p.A.
• EvolveImmune United, Inc.
• Rakuten Medical, Inc.
• Hummingbird Bioscience
• Ankyra Therapeutics, Inc.
• Bicara Therapeutics
• KaliVir Immunotherapeutics
• Immunitas Therapeutics
• Memgen, Inc.
• Boundless Bio, Inc.
• Medicenna Therapeutics, Inc.